Phase II Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.

Trial Profile

Phase II Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Cetuximab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms MesoMab
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 07 Feb 2017 Status changed from recruiting to completed.
    • 04 Dec 2014 Planned End Date changed from 1 Sep 2013 to 1 Sep 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top